Merrimack Halts Development of Pancreatic Cancer Candidate After Phase II Failure

Merrimack Pharmaceuticals said today it will cease development of its pancreatic cancer candidate MM-141 (istiratumab) following its failure in a Phase II trial.MM-141 missed its primary and secondary endpoints in the Phase II CARRIE trial ( NCT02399137 ), designed to assess the addition of the drug candidate to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels of free insulin-like growth factor-1 (IGF-1).The trial enrolled 88 pat